> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Avalo Says $462.8 Million Can Fund Operations Into 2029 As It Prepares Skin-Disease Trial
- URL: https://www.bullished.co/avalo-says-462-8-million-can-fund-operations-into-2029-as-it-prepares-skin-disease-trial-476b3540/
- Published: 2026-11-06T16:52:24.000Z
- Updated: 2026-11-06T16:52:24.000Z
- Description: The biotech plans a late-stage abdakibart trial in the first half of 2027; higher operating costs accompanied a narrower quarterly loss.
- Author: Matteo Parrino
- Tags: SEC Filings, AVTX, Industry: Healthcare

[Avalo Therapeutics](https://www.bullished.co/tag/avtx/), which develops treatments for immune-mediated inflammatory diseases, had $462.8 million in cash, cash equivalents and investments at September 30 and expects that money to support operations into 2029\. The company outlined that funding outlook in Thursday’s earnings release accompanying its [SEC filing](https://www.sec.gov/Archives/edgar/data/0001534120/000153412026000056/avtx-20261105.htm?ref=bullished.co), as it prepares a late-stage trial of its lead skin-disease treatment.

## Cash Behind The Clinical Plans

Avalo used [$49.2 million](https://www.sec.gov/Archives/edgar/data/0001534120/000153412026000056/ex-9913q2026earningsrelease.htm?ref=bullished.co) to operate during the first nine months of 2026\. Its development spending now spans abdakibart and AVTX-010, antibodies targeting IL-1β, a protein involved in inflammation.

Abdakibart is being developed for hidradenitis suppurativa, a chronic inflammatory skin condition. Avalo holds an exclusive worldwide license from Eli Lilly. The company has no approved products to sell and depends on contract manufacturers rather than its own manufacturing facilities.

AVTX shares rose about 2% to $6.79 in Friday trading.

## Higher Costs, A Smaller Loss

Third-quarter research spending totaled $15.0 million, $1.4 million above the year-earlier quarter. Manufacturing work for both drug candidates, stock-based pay and personnel expenses drove the increase. Lower clinical costs partly offset those increases as activity associated with the mid-stage abdakibart trial declined after its initial results in May 2026.

Administrative expenses reached $8.4 million, an increase of $2.8 million from the third quarter of 2025, chiefly because of stock-based pay and personnel costs. Total operating expenses increased by $4.2 million.

The quarterly net loss nevertheless narrowed by $11.7 million to $18.9 million, mainly because of a change in the valuation of a derivative liability—a financial obligation whose value is remeasured. That valuation line produced $210,000 of income, compared with a $12.530 million expense a year earlier. Net interest income also increased, to $4.249 million from $1.114 million.

Basic and diluted loss per share fell to $0.34 from $2.19\. The per-share comparison also uses a larger share base: weighted-average common shares were 55,060,404, versus 14,000,451 in the year-earlier quarter.

## Abdakibart Heads Toward Regulatory Feedback

Avalo expects FDA feedback on its proposed abdakibart development plan by year-end 2026 and plans to begin a late-stage program intended to support approval in the first half of 2027\. The company presented results from its mid-stage trial at the 2026 European Academy of Dermatology and Venereology Congress in an oral presentation and a poster.

Garry Neil, Avalo’s chief executive officer, cited the “potential for [once-monthly administration](https://www.sec.gov/Archives/edgar/data/0001534120/000153412026000056/ex-9913q2026earningsrelease.htm?ref=bullished.co)” in Thursday’s statement. Neil said: “Our priority is to translate these findings into a rigorous Phase 3 program designed to establish clinically meaningful and durable benefit, informed by upcoming regulatory feedback.”

AVTX-010 is designed to last longer while preserving abdakibart’s drug activity and specificity. Avalo is developing it for potential treatment of hidradenitis suppurativa and other inflammatory diseases.

Avalo anticipates submitting an application to begin human testing of AVTX-010 in the first half of 2027—the same period in which it plans to start the late-stage abdakibart program.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Avalo Therapeutics, Inc. (AVTX)](https://www.sec.gov/Archives/edgar/data/0001534120/000153412026000056/avtx-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex-9913q2026earningsrelease.htm — Avalo Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001534120/000153412026000056/ex-9913q2026earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Avalo Therapeutics Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/05/3396252/0/en/avalo-therapeutics-reports-third-quarter-2026-financial-results-and-recent-business-updates.html?ref=bullished.co) — globenewswire.com
- [Avalo Therapeutics to Participate in Upcoming Investor](https://www.globenewswire.com/news-release/2026/11/02/3393691/0/en/avalo-therapeutics-to-participate-in-upcoming-investor-conferences.html?ref=bullished.co) — globenewswire.com

### More on Avalo Therapeutics

- [Trails Edge Capital Takes A 5.2% Passive Stake In Avalo Therapeutics](https://www.bullished.co/trails-edge-capital-takes-a-5-2-passive-stake-in-avalo-therapeutics-9e5d7c8e/)

[All Avalo Therapeutics (AVTX) coverage →](https://www.bullished.co/tag/avtx/)